A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

432

Participants

Timeline

Start Date

December 29, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

July 31, 2027

Conditions

Advanced Urothelial Carcinoma

Interventions

DRUG

9MW2821

1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle

DRUG

Chemotherapy

75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY